Finepoint Capital’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-905,384
| Closed | -$13.9M | – | 25 |
|
|
2024
Q3 | $13.9M | Hold |
905,384
| – | – | 1.01% | 12 |
|
|
2024
Q2 | $14.7M | Buy |
905,384
+64,931
| +8% | +$1.06M | 4.18% | 9 |
|
|
2024
Q1 | $15.5M | Buy |
840,453
+70,800
| +9% | +$1.31M | 3.99% | 11 |
|
|
2023
Q4 | $24.1M | Buy |
769,653
+213,100
| +38% | +$6.67M | 7.6% | 2 |
|
|
2023
Q3 | $11.6M | Sell |
556,553
-290,400
| -34% | -$6.05M | 5.78% | 11 |
|
|
2023
Q2 | $20.3M | Sell |
846,953
-69,400
| -8% | -$1.66M | 7.02% | 3 |
|
|
2023
Q1 | $17.2M | Sell |
916,353
-260,477
| -22% | -$4.9M | 6.59% | 4 |
|
|
2022
Q4 | $18.7M | Buy |
1,176,830
+65,800
| +6% | +$1.05M | 6.06% | 4 |
|
|
2022
Q3 | $18.2M | Buy |
1,111,030
+403,830
| +57% | +$6.61M | 5.98% | 5 |
|
|
2022
Q2 | $9.96M | Buy |
+707,200
| New | +$9.96M | 3.45% | 17 |
|